Psilocybin

Reunion Neuroscience has completed patient dosing in its RECONNECT Phase 2 trial evaluating RE104, a short-duration psychedelic therapy for postpartum depression, with topline results expected in Q3 2025.

Tryptamine Therapeutics has appointed Herwig Janssen, a former Johnson & Johnson executive with 40+ years of pharmaceutical experience, as its new non-executive chairman effective May 12.

Republican lawmakers in Texas are pushing legislation to allocate $25 million for the first FDA-approved clinical trials of ibogaine, a psychoactive compound derived from the West African iboga plant.

Hawaii's House Finance Committee unanimously approved a Senate-passed bill establishing a two-year pilot program for psychedelic-assisted therapy research, potentially providing $4 million in combined public-private funding.

Emergency room patients treated for psychedelic use face a 2.6-fold higher risk of death within five years compared to the general population, with particularly elevated risks for suicide, cancer, and overdose.